More about

Metabolic Dysfunction-Associated Steatotic Liver Disease

News
January 06, 2024
3 min read
Save

Gut Check-in: Healio Gastroenterology recaps trends that will shape GI practice in 2024

From a shift in nomenclature for steatotic liver disease to how a boom in live biotherapeutics will revamp treatment for Clostridioides difficile infection, Healio was at the forefront of gastroenterology and hepatology coverage in 2023.

News
December 18, 2023
2 min read
Save

Nomenclature change brings new opportunities for research, drug development

The renaming of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease to metabolic dysfunction-associated steatohepatitis and metabolic dysfunction-associated steatotic liver disease is a long time coming.

News
December 18, 2023
10 min read
Save

No patient left behind: MASLD rebranding provides ‘affirmative diagnosis’ without stigma

In June 2023, 74% of respondents from a multinational, multisociety Delphi process agreed that the term nonalcoholic fatty liver disease was “sufficiently flawed” and 89% preferred nomenclature that described the underlying cause of disease.

News
December 08, 2023
2 min read
Save

More education needed to help PCPs ‘feel confident’ treating, managing MASLD

BOSTON — Although primary care physicians play a vital role in managing metabolic dysfunction-associated steatotic liver disease, many are not following guidance on screening, risk stratification or referrals, according to research.

News
December 07, 2023
1 min read
Save

Patients with MASLD lost less weight after bariatric surgery, study finds

BOSTON — Patients with metabolic dysfunction-associated steatotic liver disease who underwent bariatric surgery lost less weight over 5 years than those without MASLD, according to research presented at The Liver Meeting.

News
November 28, 2023
2 min read
Save

Aldafermin 3 mg significantly reduced Enhanced Liver Fibrosis score in MASH

BOSTON — Treatment with aldafermin 3 mg appeared to be well-tolerated and significantly reduced Enhance Liver Fibrosis score after 48 weeks among patients with metabolic dysfunction-associated steatohepatitis, according to a presenter.

News
November 22, 2023
2 min read
Save

Up to 67% of patients achieve MASH resolution at 36 weeks with efruxifermin

BOSTON — Treatment with efruxifermin resulted in “clinically meaningful” but not yet statistically significant benefit at 36 weeks in cirrhotic patients with metabolic dysfunction-associated steatohepatitis, according to late-breaking data.

News
November 21, 2023
3 min read
Save

Retatrutide 12 mg resolved steatosis in more than 90% of patients with obesity, MASLD

BOSTON — Treatment with retatrutide at 8 mg and 12 mg resulted in substantial reductions in liver fat in patients with obesity and metabolic dysfunction-associated steatotic liver disease, according to a presenter at The Liver Meeting.

News
November 21, 2023
2 min read
Save

High ultra-processed food intake linked to increased MASLD risk in adolescents, adults

Increased consumption of ultra-processed foods was associated with higher odds of developing metabolic dysfunction-associated steatotic liver disease in both adolescents and adults, according to research presented at The Liver Meeting.

News
November 21, 2023
2 min read
Save

Low-dose aspirin ‘potential therapeutic option’ for MASLD, markedly reduces steatosis

BOSTON — Low-dose aspirin significantly reduced steatosis in patients with metabolic dysfunction-associated steatotic liver disease and improved markers of liver inflammation and fibrosis, according to data presented at The Liver Meeting.

View more